|Bid||77.56 x 1200|
|Ask||77.67 x 1200|
|Day's Range||75.05 - 78.25|
|52 Week Range||30.02 - 81.35|
|Beta (5Y Monthly)||1.81|
|PE Ratio (TTM)||42.27|
|Earnings Date||Apr 28, 2021 - May 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||85.60|
Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data ReviewMORRISVILLE, N.C. and SALT LAKE CITY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Protocol First, Inc., a software solutions provider focused on accelerating clinical research, today announced a novel strategic partnership aimed at driving faster, more efficient clinical trials. The partnership is expected to optimize data integration with Electronic Health Record Systems and support Remote Source Data Review, further extending a multi-year, pre-existing relationship between Syneos Health and Protocol First. The collaboration responds to the increasing demand from biopharmaceutical customers for digital solutions that break down silos between Sites, Sponsors, CROs and functional areas to accelerate the collection and review of clinical trial research data. The partnership further extends the expertise of Syneos Health with Protocol First’s products by delivering advanced knowledge transfer, product access, certification and other competitive benefits. The partnership grants Syneos Health a “First-to-Market” certification in terms of training and knowledge transfer for configuration of the Protocol First software products. The enhanced collaboration furthers the ability of Syneos Health to combine Protocol First’s proprietary software solutions that integrate data from leading EHR systems into electronic data capture (EDC) with operational insights from Syneos Health Dynamic Assembly® network — an open ecosystem of best-of-breed data and technology collaborators — to deliver fit-for-purpose customer solutions. Combining these approaches allows the companies to address customer nuances related to trial protocols, capturing and analyzing clinical trial data faster and more efficiently with the goal of accelerating product time-to-market. Syneos Health will use Protocol First’s unique P1 Source Upload solution for remote monitoring. “This partnership with Protocol First further strengthens our Dynamic Assembly network and supports our strategy to bring creative solutions to research sites. By offering cutting-edge, innovative technologies and critical insights, we are working to help our clients bring medicines to market faster,” said Paul Colvin, President, Clinical Solutions, for Syneos Health. “Protocol First has been a leader in developing next-generation technology solutions for complex clinical trials, and we’re pleased that we could extend our partnership to improve patients’ lives.” “Syneos Health, as a first mover participant in our Protocol First Partnership, represents a milestone in the growth and adoption of our innovative software solutions, including Clinical Pipe and P1 Source Upload for remote monitoring. It is a harbinger of the transformation of clinical research to a digital model that ensures end-to-end data traceability in the most complex ‘precision medicine’ trials, while supporting remote and decentralized study execution,” said Hugh P. Levaux, Ph.D., Founder and CEO for Protocol First. Building on the partnership and in response to the COVID-19 pandemic, Syneos Health and Protocol First recently developed and published a white paper to further demonstrate how a proven technology solution can enable CRAs to perform their tasks remotely. The white paper, Ensuring Data Quality During a Pandemic: How Innovative Technology Supports Remote Source Document Review, can be found here. About Syneos HealthSyneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 25,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast. About Protocol FirstProtocol First, Inc., founded in 2015 and headquartered in Salt Lake City, UT, develops next-generation technology solutions for complex clinical trials in the Life Sciences industry. In addition to its flagship Protocol First suite of cloud-based solutions (eProtocol, Source Upload and EDC), Protocol First has launched Clinical Pipe, the industry's first connector app that offers system-agnostic EHR-to-EDC interoperability. The application supports major EHR and EDC systems including Epic, Cerner, Allscripts and Athena, as well as Medidata Rave, Oracle InForm, and its own P1 platform. For additional information visit www.protocolfirst.com. Investor Relations Contact:Press/Media Contact:Ronnie SpeightGary GatyasSenior Vice President, Investor RelationsExecutive Director, External Communications+1 919 745 2745+1 908 763 3428 Investor.Relations@firstname.lastname@example.org
Right now, Syneos Health Inc. (NASDAQ:SYNH) share price is at $75.77, after a 1.90% increase. Moreover, over the past month, the stock decreased by 0.42%, but in the past year, increased by 12.84%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 6.86%. The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. View more earnings on SYNH Depending on the particular phase of a business cycle, some industries will perform better than others. Compared to the aggregate P/E ratio of the 96.84 in the Life Sciences Tools & Services industry, Syneos Health Inc. has a lower P/E ratio of 40.63. Shareholders might be inclined to think that the stock might perform worse than its industry peers. It's also possible that the stock is undervalued. P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors can become unable to attain key insights from trailing earnings. See more from BenzingaClick here for options trades from BenzingaSyneos Health: Q4 Earnings InsightsEarnings Scheduled For February 18, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
SYNH earnings call for the period ending December 31, 2020.